Schrödinger, Bayer collaborate to co-develop de novo design technology to accelerate drug discovery
The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the identification and optimization of potential new therapeutic candidates.